Grade ≥3 hematologic AEs, including neutropenia, resolved to grade ≤2 in 8 days, indicating effective management was achieved with dose modifications and/or supportive care interventions, including G-CSF. This evidence concerns the gene CSF3 and Decreased total neutrophil count.